Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up

By Tiippana-Kinnunen T   Paimela L   Kautiainen H   Laasonen L   Leirisalo-Repo M  

Scandinavian Journal of Rheumatology, Vol. 39, Iss. 1, 2010-05 ,pp. : 12-18

Informa Healthcare

Access to resources Recommend Favorite

Recurrent infections in a rheumatoid arthritis patient with a primary immunodeficiency, treated with conventional and biologic disease-modifying anti-rheumatic drugs

By Diamantopoulos Andreas  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 295-297

Springer Publishing Company

Access to resources Recommend Favorite

Distribution of Podoplanin in Synovial Tissues in Rheumatoid Arthritis Patients Using Biologic or Conventional Disease-Modifying Anti-Rheumatic Drugs

By  

Current Rheumatology Reviews, Vol. 13, Iss. 1, 2017-01 ,pp. : 72-78

Bentham Science Publishers

Access to resources Recommend Favorite

Intensifying treatment of rheumatoid arthritis with combinations of traditional disease-modifying anti-rheumatic drugs among patients with persistent disease did not reduce the need for large joint surgery

By Kononoff A.   Heiskanen J.   Lumiaho J.   Kautiainen H.   Kaipiainen-Seppänen O.  

Scandinavian Journal of Rheumatology, Vol. 36, Iss. 6, 2007-01 ,pp. : 424-427

Informa Healthcare

Access to resources Recommend Favorite

Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors

By Kita Junko  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 195-201

Springer Publishing Company

Access to resources Recommend Favorite